RadMD
RadMD is a medical imaging contract research organization providing centralized imaging core lab services—including oncology, CNS, diagnostic imaging agents, and AI validation—to pharmaceutical and biotech sponsors of clinical trials. A subsidiary of Medica Group.
- Company typePrivate
- Founded2022
- HeadquartersConshohocken, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What RadMD does
RadMD is an Imaging Contract Research Organization (iCRO) that delivers specialized medical imaging core lab services to pharmaceutical and biotech sponsors of clinical trials. The company supports trial imaging activities from Phase 1 through Phase 3 and regulatory submission, with documented scale of 1,000+ research sites trained, 700+ trial design and analysis projects, and 50+ regulatory submissions across global authorities (INDs, NDAs, PMAs). Therapeutic area specializations span oncology (particularly early-phase), central nervous system (CNS) disorders, diagnostic imaging agents, and AI validation for imaging algorithms.
The company's offering is structured as a centralized imaging core lab platform. Core capabilities include imaging endpoint design, central image review and analysis, blinded independent central review (BICR)-style assessments, a Reader Group of expert radiologists providing independent blinded reads, and site/reader training aimed at reducing site read errors that inflate trial cost. The technology stack is service-led rather than product-led; the proprietary element is the expert reader network, accumulated imaging protocols, and regulatory submission experience rather than a discrete software platform. AI is present as a validation service line for third-party AI imaging algorithms, not as an internal AI development capability.
RadMD operates a B2B professional services revenue model with enterprise field sales targeting pharma and biotech trial sponsors; pricing is not publicly disclosed and requires direct consultation. The company has a small reported headcount (1-10), suggesting a leveraged model where most reader and analytical work is performed by contracted specialists through the Reader Group. RadMD is privately held and is a subsidiary of Medica Group Ltd, a UK-headquartered medical imaging reporting organization that provides operational infrastructure and a UK delivery location in Hastings, East Sussex. The company is headquartered at 1100 East Hector Street, Suite 450, Conshohocken, PA, with leadership comprising co-founders Kohkan Shamsi and Rick Patt, Chief Commercial Officer Judy Currier, and Chief Compliance Officer David Julyk.
RadMD firmographics
Firmographics- Name
- RadMD
- Legal name
- RadMD
- Website
- https://rad-md.net
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RadMD is a medical imaging contract research organization providing centralized imaging core lab services—including oncology, CNS, diagnostic imaging agents, and AI validation—to pharmaceutical and biotech sponsors of clinical trials. A subsidiary of Medica Group.
- Ownership category
- akta.pro rank
Where RadMD is headquartered
LocationHeadquarters
- HQ city
- Conshohocken
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
RadMD business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Imaging Core Lab Services: B2B professional services providing medical imaging expertise for clinical trials including imaging endpoint design, image review and analysis, and regulatory submission support
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
RadMD product offering
Product offeringCore offering
RadMD is a medical imaging core lab (iCRO) that provides imaging management solutions for clinical trials conducted by pharmaceutical and biotech sponsors. Its services include imaging endpoint design, centralized image review and analysis, expert radiologist reader assessments, site and reader training, and validation of AI-powered imaging tools, supporting trials from Phase 1 through Phase 3 and global regulatory submission. The company is part of Medica Group Ltd and serves therapeutic areas including oncology, CNS, and diagnostic imaging agents.
Product overview
RadMD operates as a unified medical imaging core lab platform providing end-to-end imaging services for clinical trials. The core offering is the Imaging Core Lab service, supported by specialized therapeutic area modules (Oncology, CNS), diagnostic imaging agent validation, AI validation for imaging tools, and a Reader Group network. Site Training services round out the portfolio by ensuring research sites are properly equipped to capture and submit quality imaging data. Together, these products enable sponsors to centralize imaging endpoint assessment from Phase 1 through Phase 3 and regulatory submission.
Differentiator
Problem solved
Functional benefit
Products and services
- Imaging Core Lab
Quantifiable outcome
- Reduces trial costs by eliminating site read errors that inflate expenses and muddy imaging data results
Companies that use RadMD
Customer profileSegments4 records
Ideal customer profiles2 records
RadMD technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RadMD partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Medica Group Ltd / Medica Reporting LimitedcoreRadMD is part of Medica Group, a global medical imaging reporting organization. Medica Group provides operational infrastructure and global scale supporting RadMD's core lab services. The parent company operates from Hastings, East Sussex, UK, providing reporting and imaging services internationally.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
RadMD competitors and assessment
Company assessmentEmerging players
- Cerveau Technologies: Emerging imaging biomarker company focused on tau PET ligands and CNS imaging. Comparable in CNS/neurodegenerative imaging specialization though narrower in therapeutic and service scope than RadMD.
- Pharmtrace: European imaging CRO providing central reading and quantitative image analysis for clinical trials. Comparable specialty iCRO with similar service model and trial-sponsor customer base.
Broad incumbents
- Medpace Holdings: Mid-to-large CRO with growing imaging capabilities supporting oncology and specialty trials. Competes for sponsor trial awards where imaging endpoints are integrated with broader clinical operations.
- ICON plc: Top-5 global CRO with full-service clinical operations including imaging core lab capabilities. Larger broad incumbent that competes for full-service trial awards where imaging is one component of a broader engagement.
Direct peers
- IXICO plc: UK-based imaging CRO providing image analysis and central reading services for neurological and oncology clinical trials. Closely comparable specialty iCRO with similar therapeutic-area focus and trial-sponsor customer base.
- Clario (formerly Bioclinica): Major imaging core lab and clinical trial technology provider offering BICR, imaging management, and endpoint services. The most direct scaled competitor in the iCRO space across oncology, CNS, and other therapeutic areas.
- Median Technologies: Public imaging CRO specializing in image management and AI-driven lesion detection for oncology clinical trials. Comparable in oncology imaging focus and integration of AI into trial workflows.
- inviCRO: Imaging CRO offering image acquisition, analysis, and quantitative biomarker services for clinical trials. Direct comparable in trial-focused imaging services and translational research offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
RadMD social profiles
Digital presenceRadMD financial estimates
Financial estimateRevenue estimate
Valuation estimate
RadMD leadership team
Management profileNumber of profiles
Profiles4 records
RadMD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RadMD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RadMD
What does RadMD do?
RadMD is a medical imaging core lab (iCRO) that provides imaging management solutions for clinical trials conducted by pharmaceutical and biotech sponsors. Its services include imaging endpoint design, centralized image review and analysis, expert radiologist reader assessments, site and reader training, and validation of AI-powered imaging tools, supporting trials from Phase 1 through Phase 3 and global regulatory submission. The company is part of Medica Group Ltd and serves therapeutic areas including oncology, CNS, and diagnostic imaging agents.
Is RadMD a public or private company?
RadMD is a private company. It is classified as corporate owned and is currently operating.
When was RadMD founded?
RadMD was founded in 2022. It employs 1 to 10 people.
Where is RadMD based?
RadMD is headquartered in Conshohocken, United States, in the North America region.
How does RadMD make money?
One revenue line is on record: medical Imaging Core Lab Services.
Who are RadMD's main competitors?
Emerging players on record are Cerveau Technologies and Pharmtrace. Broad incumbents are Medpace Holdings and ICON plc. Direct peers are IXICO plc, Clario (formerly Bioclinica), Median Technologies and inviCRO.
Does RadMD have an API?
No public API is recorded for RadMD.